Type I interferon is selectively required by dendritic cells for immune rejection of tumors
Mark S. Diamond, Michelle Kinder, Hirokazu Matsushita et al. · The Journal of Experimental Medicine · 2011
Cancer immunoediting is the process whereby the immune system suppresses neoplastic growth and shapes tumor immunogenicity. We previously reported that type I interferon (IFN-α/β) plays a central role in this process and that hematopoietic cells represent critical targets of type I IFN's actions. However, the specific cells affected by IFN-α/β and the functional processes that type I IFN induces remain undefined. Herein, we show that type I IFN is required to initiate the antitumor response and that its actions are temporally distinct from IFN-γ during cancer immunoediting. Using mixed bone marrow chimeric mice, we demonstrate that type I IFN sensitivity selectively within the innate immune compartment is essential for tumor-specific T cell priming and tumor elimination. We further show that mice lacking IFNAR1 (IFN-α/β receptor 1) in dendritic cells (DCs; Itgax-Cre(+)Ifnar1(f/f) mice) cannot reject highly immunogenic tumor cells and that CD8α(+) DCs from these mice display defects in antigen cross-presentation to CD8(+) T cells. In contrast, mice depleted of NK cells or mice that lack IFNAR1 in granulocytes and macrophage populations reject these tumors normally. Thus, DCs and specifically CD8α(+) DCs are functionally relevant targets of endogenous type I IFN during lymphocyte-mediated tumor rejection.
Cited by 1,077 works. doi:10.1084/jem.20101158 Open-access PDF
Authors
- Mark S. Diamond
- Michelle Kinder
- Hirokazu Matsushita
- Mona Mashayekhi
- Gavin P. Dunn
- Jessica M. Archambault
- Hsiaoju S. Lee
- Cora D. Arthur
- J. Michael White
- Ulrich Kalinke
- Kenneth M. Murphy
- Robert D. Schreiber
References
- Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule.
- RAG-1-deficient mice have no mature B and T lymphocytes
- Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
- T cell receptor antagonist peptides induce positive selection
- Cancer immunoediting: from immunosurveillance to tumor escape
- Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
- Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
- IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
- Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo
- The Three Es of Cancer Immunoediting